Is MCV sT required for MCC cell proliferation?
The knockdown by Angermeyer et al. used different shRNAs (Angermeyer et al., 2013) , and directly contradict our findings that sT knockdown inhibits cell replication in MCV-MCC (Shuda et al). Since Angermeyer et al were not able to measure sT protein by immunoblotting, efficacy of knockdown could not be determined. To assess cell proliferation, Angermeyer et al used a competition assay containing mixtures of shRNAtransduced and nontransduced cells that compete with each other for growth. We instead directly measured cell proliferation using standard Wst-1 assays. To resolve this, we generated the same two sT-specific shRNAs cloned in pLKO.1-based lentiviral vector (named here sT1.RH for Roland Houben laboratory and sT2.RH) used in their study and compared them to an shRNA previously described to target sT alone (designated here as sh sT1.MS for Masahiro Shuda laboratory), an shRNA targeting both LT and sT (sh panT.MS) and a scrambled negative control shRNA (sh ctrl) (Shuda et al., 2011) . Both sh sT1.MS and sh panT.MS inhibit sT protein expression measured by quantitative LICOR immunoblotting (Figure 2A and B) and cell growth ( Figure 2C ) as previously described (Shuda et al., 2011) . One of Angermeyer et al.'s shRNA (sh sT1.RH) also inhibits sT expression and significantly inhibits MCV-MCC cell growth. Proliferation of UISO cells, however, was also reduced consistent with an off-target effect that precludes evaluating it as a targeting agent for MCV sT. The other shRNA (sh sT2.RH) has minimal (MKL-2) or no (MKL-1) sT knockdown activity ( Figure 2B ). It nonetheless inhibits MCV-MCC cell growth. Given the inability to monitor sT knockdown and off-target effects for the sT.RH shRNAs used in Angermeyer et al's knockdown studies, attempts to rescue MCC cell proliferation using combinations of LT and sT expression during sT knockdown are not interpretable.
Using the same shRNA constructs described by Angermeyer et al., we show that their conclusion that MCV sT plays no role in MCV is not correct. We recommend using sh sT1.MS, which is efficacious in sT knockdown and we are unaware of any off-target activity. Mixed cell competition assays to measure proliferation are fraught with uncertainty since paracrine effects can distort proliferation measurements and more traditional cell counting or Wst-1 measurements are preferred. Finally, as co-equal authors that independently developed T antigen shRNA knockdowns for the report describing T antigen knockdown in MCC (Houben et al., 2010) , we disagree with these authors' assertion that pan-T knockdown induces apoptosis in MCC. Weak PARP cleavage (Figure. 5B, Houben et al., 2010) can be seen in some cell lines during knockdown, but it is not universally present and Casp3 or Casp9 cleavage is completely absent. As confirmed by Angermeyer et al., MCV sT is the only known transforming oncoprotein of MCV in rodent cells while MCV LT alone is not sufficient to transform rodent fibroblast cells (Angermeyer et al., 2013; Shuda et al., 2011) . In the SV40 T antigen model of human cell transformation, expression of both LT and sT is required (Hahn et al., 1999) . Taking into consideration the higher tumorigenic barrier in human cells as compared to rodent cells and that the spliced sT isoform is expressed together with LT in most MCC (Shuda et al., 2011) , it is likely that MCV sT co-contributes with MCV LT to MCC carcinogenesis. 
